Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 3/2007

01-03-2007 | Original Paper

Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells

Authors: Peter Ebeling, P. Bach, U. Sorg, A. Schneider, T. Trarbach, D. Dilloo, H. Hanenberg, S. Niesert, S. Seeber, T. Moritz, M. Flasshove

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2007

Login to get access

Abstract

Purpose

Although gene transfer with retroviral vectors has shown distinct clinical success in defined settings, efficient genetic manipulation of hematopoietic progenitor cells remains a challenge. To address this issue we have evaluated different transduction protocols and retroviral constructs in the non-obese diabetes (NOD)/severe combined immunodeficiency disease (SCID) xenograft model.

Methods

An extended transduction protocol requiring 144 h of in vitro manipulation was compared to a more conventional protocol requiring 96 h only.

Result

While pretransplantation analysis of cells transduced with a retroviral vector, expressing the enhanced green fluorescent protein (EGFP) marker gene, demonstrated significantly higher overall transduction rates for the extended protocol (33.6 ± 2.3 vs. 22.1 ± 3.8%), EGFP expression in CD34+ cells before transplantation (4.0 ± 0.9 vs. 11.6 ± 2.5%), engraftment of human cells in NOD/SCID bone marrow 4 weeks after transplantation (4.5 ± 1.7 vs. 36.5 ± 9.4%) and EGFP expression in these cells (0 ± 0 vs. 11.3 ± 2.8%) were significantly impaired. When the 96 h protocol was used in combination with the spleen focus forming virus (SFFV)/murine embryonic stem cell (MESV) hybrid vector SFβ11-EGFP, high transduction rates for CD45+ (41.0 ± 5.3%) and CD34+ (38.5 ± 3.7%) cells prior to transplantation, as well as efficient human cell engraftment in NOD/SCID mice 4 weeks after transplantation (32.4 ± 3.5%), was detected. Transgene expression was observed in B-lymphoid (15.9 ± 2.0%), myeloid (36.5 ± 3.5%) and CD34+ cells (10.1 ± 1.5%).

Conclusion

Our data show that CD34+ cells maintained in cytokines for multiple days may differentiate and loose their capacity to contribute to the haematological reconstitution of NOD/SCID mice. In addition, the SFFV/MESV hybrid vector SFβ11-EGFP allows efficient transduction of and gene expression in haematopoietic progenitor cells.
Literature
Ahmed F, Ings SJ, Pizzey AR, Blundell MP, Thrasher AJ, Ye HT, Fahey A, Linch DC, Yong KL (2004) Impaired bone marrow homing of cytokine-activated CD34+ cells in the NOD/SCID model. Blood 103:2079–2087PubMedCrossRef
Ballen K, Becker PS, Greiner D, Valinski H, Shearin D, Berrios V, Dooner G, Hsieh CC, Wuu J, Shultz L, Cerny J, Leif J, Stewart FM, Quesenberry P (2000) Effect of ex vivo cytokine treatment on human cord blood engraftment in NOD-scid mice. Br J Haematol 108:629–640PubMedCrossRef
Barquinero J, Segovia JC, Ramirez M, Limon A, Guenechea G, Puig T, Briones J, Garcia J, Bueren JA (2000) Efficient transduction of human hematopoietic repopulating cells generating stable engraftment of transgene-expressing cells in NOD/SCID mice. Blood 95:3085–3093PubMed
Baum C, Eckert HG, Stockschlader M, Just U, Hegewisch-Becker S, Hildinger M, Uhde A, John J, Ostertag W (1996) Improved retroviral vectors for hematopoietic stem cell protection and in vivo selection. J Hematother 5:323–329PubMed
Bjorgvinsdottir H, Bryder D, Sitnicka E, Ramsfjell V, De Jong I, Olsson K, Rusterholz C, Karlsson S, Jacobsen SE (2002) Efficient oncoretroviral transduction of extended long-term culture-initiating cells and NOD/SCID repopulating cells: enhanced reconstitution with gene-marked cells through an ex vivo expansion approach. Hum Gene Ther 13:1061–1073PubMedCrossRef
Bordignon C, Roncarolo MG (2002) Therapeutic applications for hematopoietic stem cell gene transfer. Nat Immunol 3:318–321PubMedCrossRef
Carstanjen D, Dutt P, Moritz T (2001) Heparin inhibits retrovirus binding to fibronectin as well as retrovirus gene transfer on fibronectin fragments. J Virol 75:6218–6222PubMedCrossRef
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669–672PubMedCrossRef
Danet GH, Lee HW, Luongo JL, Simon MC, Bonnet DA (2001) Dissociation between stem cell phenotype and NOD/SCID repopulating activity in human peripheral blood CD34(+) cells after ex vivo expansion. Exp Hematol 29:1465–1473PubMedCrossRef
Dao MA, Hashino K, Kato I, Nolta JA (1998) Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem and progenitor cells. Blood 92:4612–4621PubMed
Demaison C, Brouns G, Blundell MP, Goldman JP, Levinsky RJ, Grez M, Kinnon C, Thrasher AJ (2000) A defined window for efficient gene marking of severe combined immunodeficient-repopulating cells using a gibbon ape leukemia virus-pseudotyped retroviral vector. Hum Gene Ther 11:91–100PubMedCrossRef
Denning-Kendall P, Singha S, Bradley B, Hows J (2003) Cytokine expansion culture of cord blood CD34+ cells induces marked and sustained changes in adhesion receptor and CXCR4 expressions. Stem Cells 21:61–70PubMedCrossRef
Dick JE, Kamel-Reid S, Murdoch B, Doedens M (1991) Gene transfer into normal human hematopoietic cells using in vitro and in vivo assays. Blood 78:624–634PubMed
Donahue RE, Sorrentino BP, Hawley RG, An DS, Chen IS, Wersto RP (2001) Fibronectin fragment CH-296 inhibits apoptosis and enhances ex vivo gene transfer by murine retrovirus and human lentivirus vectors independent of viral tropism in nonhuman primate CD34+ cells. Mol Ther 3:359–367PubMedCrossRef
Dorrell C, Gan OI, Pereira DS, Hawley RG, Dick JE (2000) Expansion of human cord blood CD34(+)CD38(−) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. Blood 95:102–110PubMed
Dunbar CE, Takatoku M, Donahue RE (2001) The impact of ex vivo cytokine stimulation on engraftment of primitive hematopoietic cells in a non-human primate model. Ann NY Acad Sci 938:236–244; discussion 244–245
Flores-Guzman P, Gutierrez-Rodriguez M, Mayani H (2002) In vitro proliferation, expansion, and differentiation of a CD34+ cell-enriched hematopoietic cell population from human umbilical cord blood in response to recombinant cytokines. Arch Med Res 33:107–114PubMedCrossRef
Gatlin J, Melkus MW, Padgett A, Kelly PF, Garcia JV (2001) Engraftment of NOD/SCID mice with human CD34(+) cells transduced by concentrated oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. J Virol 75:9995–9999PubMedCrossRef
Gothot A, Giet O, Huygen S, Beguin Y (2003) Binding and migration across fibronectin and VCAM-1 of cycling hematopoietic progenitor cells. Leuk Lymphoma 44:1379–1383PubMedCrossRef
Guenechea G, Segovia JC, Albella B, Lamana M, Ramirez M, Regidor C, Fernandez MN, Bueren JA (1999) Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord blood cells. Blood 93:1097–1105PubMed
Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA (1996) Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 2:876–882PubMedCrossRef
Hanenberg H, Hashino K, Konishi H, Hock RA, Kato I, Williams DA (1997) Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. Hum Gene Ther 8:2193–2206PubMed
Hanenberg H, Batish SD, Pollok KE, Vieten L, Verlander PC, Leurs C, Cooper RJ, Gottsche K, Haneline L, Clapp DW, Lobitz S, Williams DA, Auerbach AD (2002) Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. Exp Hematol 30:410–420PubMedCrossRef
Hawley RG, Lieu FH, Fong AZ, Hawley TS (1994) Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1:136–138PubMed
Hennemann B, Conneally E, Pawliuk R, Leboulch P, Rose-John S, Reid D, Chuo JY, Humphries RK, Eaves CJ (1999) Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol variables. Exp Hematol 27:817–825PubMedCrossRef
van Hennik PB, Verstegen MM, Bierhuizen MF, Limon A, Wognum AW, Cancelas JA, Barquinero J, Ploemacher RE, Wagemaker G (1998) Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice. Blood 92:4013–4022PubMed
Hildinger M, Abel KL, Ostertag W, Baum C (1999) Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol 73:4083–4089PubMed
Hogan CJ, Shpall EJ, Keller G (2002) Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci USA 99:413–418PubMedCrossRef
Horn PA, Topp MS, Morris JC, Riddell SR, Kiem HP (2002) Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. Blood 100:3960–3967PubMedCrossRef
Horn PA, Thomasson BM, Wood BL, Andrews RG, Morris JC, Kiem HP (2003) Distinct hematopoietic stem/progenitor cell populations are responsible for repopulating NOD/SCID mice compared with nonhuman primates. Blood 102:4329–4335PubMedCrossRef
Horwitz ME, Malech HL, Anderson SM, Girard LJ, Bodine DM, Orlic D (1999) Granulocyte colony-stimulating factor mobilized peripheral blood stem cells enter into G1 of the cell cycle and express higher levels of amphotropic retrovirus receptor mRNA. Exp Hematol 27:1160–1167PubMedCrossRef
Kelly PF, Carrington J, Nathwani A, Vanin EF (2001) RD114-pseudotyped oncoretroviral vectors. Biological and physical properties. Ann NY Acad Sci 938:262–276; discussion 276–277
Kinsella TM, Nolan GP (1996) Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 7:1405–1413PubMed
Larochelle A, Vormoor J, Hanenberg H, Wang JC, Bhatia M, Lapidot T, Moritz T, Murdoch B, Xiao XL, Kato I, Williams DA, Dick JE (1996) Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med 2:1329–1337PubMedCrossRef
Leurs C, Jansen M, Pollok KE, Heinkelein M, Schmidt M, Wissler M, Lindemann D, Von Kalle C, Rethwilm A, Williams DA, Hanenberg H (2003) Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells. Hum Gene Ther 14:509–519PubMedCrossRef
Lewis ID, Almeida-Porada G, Du J, Lemischka IR, Moore KA, Zanjani ED, Verfaillie CM (2001) Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system. Blood 97:3441–3449PubMedCrossRef
Liu B, Buckley SM, Lewis ID, Goldman AI, Wagner JE, van der Loo JC (2003) Homing defect of cultured human hematopoietic cells in the NOD/SCID mouse is mediated by Fas/CD95. Exp Hematol 31:824–832PubMedCrossRef
Ma YP, Zhou P, Xiao J (2002) [Expression and function of CD95/fas antigen and Bcl-2 on cord blood hematopoietic progenitor cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 10:13–16PubMed
MacNeill EC, Hanenberg H, Pollok KE, van der Loo JC, Bierhuizen MF, Wagemaker G, Williams DA (1999) Simultaneous infection with retroviruses pseudotyped with different envelope proteins bypasses viral receptor interference associated with colocalization of gp70 and target cells on fibronectin CH-296. J Virol 73:3960–3967PubMed
Moritz T, Patel VP, Williams DA (1994) Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors. J Clin Invest 93:1451–1457PubMedCrossRef
Moritz T, Dutt P, Xiao X, Carstanjen D, Vik T, Hanenberg H, Williams DA (1996) Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood 88:855–862PubMed
Murray L, Luens K, Tushinski R, Jin L, Burton M, Chen J, Forestell S, Hill B (1999) Optimization of retroviral gene transduction of mobilized primitive hematopoietic progenitors by using thrombopoietin, Flt3, and Kit ligands and RetroNectin culture. Hum Gene Ther 10:1743–1752PubMedCrossRef
Ng YY, Bloem AC, van Kessel B, Lokhorst H, Logtenberg T, Staal FJ (2002) Selective in vitro expansion and efficient retroviral transduction of human CD34+ CD38- haematopoietic stem cells. Br J Haematol 117:226–237PubMedCrossRef
Novelli EM, Cheng L, Yang Y, Leung W, Ramirez M, Tanavde V, Enger C, Civin CI (1999) Ex vivo culture of cord blood CD34+ cells expands progenitor cell numbers, preserves engraftment capacity in nonobese diabetic/severe combined immunodeficient mice, and enhances retroviral transduction efficiency. Hum Gene Ther 10:2927–2940PubMedCrossRef
Orlic D, Girard LJ, Anderson SM, Pyle LC, Yoder MC, Broxmeyer HE, Bodine DM (1998) Identification of human and mouse hematopoietic stem cell populations expressing high levels of mRNA encoding retrovirus receptors. Blood 91:3247–3254PubMed
Piacibello W, Bruno S, Sanavio F, Droetto S, Gunetti M, Ailles L, Santoni de Sio F, Viale A, Gammaitoni L, Lombardo A, Naldini L, Aglietta M (2002) Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. Blood 100:4391–4400PubMedCrossRef
Rice AM, Wood JA, Milross CG, Collins CJ, Case J, Vowels MR, Nordon RE (2001) Prolonged ex vivo culture of cord blood CD34(+) cells facilitates myeloid and megakaryocytic engraftment in the non-obese diabetic severe combined immunodeficient mouse model. Br J Haematol 114:433–443PubMedCrossRef
Sabatino DE, Do BQ, Pyle LC, Seidel NE, Girard LJ, Spratt SK, Orlic D, Bodine DM (1997) Amphotropic or gibbon ape leukemia virus retrovirus binding and transduction correlates with the level of receptor mRNA in human hematopoietic cell lines. Blood Cells Mol Dis 23:422–433PubMedCrossRef
Sellers SE, Tisdale JF, Agricola BA, Donahue RE, Dunbar CE (2004) The presence of the carboxy-terminal fragment of fibronectin allows maintenance of non-human primate long-term hematopoietic repopulating cells during extended ex vivo culture and transduction. Exp Hematol 32:163–170PubMedCrossRef
Takatoku M, Sellers S, Agricola BA, Metzger ME, Kato I, Donahue RE, Dunbar CE (2001) Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates. J Clin Invest 108:447–455PubMedCrossRef
Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:346–358PubMedCrossRef
Trarbach T, Greifenberg S, Bardenheuer W, Elmaagacli A, Hirche H, Flasshove M, Seeber S, Moritz T (2000) Optimized retroviral transduction protocol for human progenitor cells utilizing fibronectin fragments. Cytotherapy 2:429–438PubMedCrossRef
Yokota T, Oritani K, Mitsui H, Aoyama K, Ishikawa J, Sugahara H, Matsumura I, Tsai S, Tomiyama Y, Kanakura Y, Matsuzawa Y (1998) Growth-supporting activities of fibronectin on hematopoietic stem/progenitor cells in vitro and in vivo: structural requirement for fibronectin activities of CS1 and cell-binding domains. Blood 91:3263–3272PubMed
Metadata
Title
Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells
Authors
Peter Ebeling
P. Bach
U. Sorg
A. Schneider
T. Trarbach
D. Dilloo
H. Hanenberg
S. Niesert
S. Seeber
T. Moritz
M. Flasshove
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 3/2007
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-006-0158-9

Other articles of this Issue 3/2007

Journal of Cancer Research and Clinical Oncology 3/2007 Go to the issue

Original Paper

Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines

Erratum

The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype

Original Paper

Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma

Original Paper

Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival

Original Paper

Human xenograft osteosarcoma models with spontaneous metastasis in mice: clinical relevance and applicability for drug testing

Original Paper

Roles of EGFR-Stat3 signal pathway in carcinogenesis of experimental hepatoma in rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits